BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
BridgeBio Oncology Therapeutics: Poised To Bank On The KRAS Revolution
BridgeBio Oncology Therapeutics is advancing differentiated KRAS inhibitors, targeting both active and inactive KRAS conformations in solid tumors, notably pancreatic cancer. BridgeBio Oncology's lead candidate BBO-11818 and G12C-specific BBO-8520 both hold FDA Fast Track designation, with early data showing promising tolerability and response rates. Strong cash position ($373.7M at 2025 year-end) provides a runway into 2028, supporting clinical milestones and mitigating near-term funding risk.
BridgeBio Oncology Therapeutics, Inc. (BBOT) Discusses Clinical Data Updates for BBO-8520, BBO-11818, and BBO-10203 Transcript
BridgeBio Oncology Therapeutics, Inc. (BBOT) Discusses Clinical Data Updates for BBO-8520, BBO-11818, and BBO-10203 Transcript
BridgeBio Oncology Therapeutics: Promising KRAS Drug Developer - In My View, At Least
BridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation small molecule therapeutics, aiming to surpass current market leaders. BBOT's lead candidate, BBO-8520, demonstrated a strong overall response rate in early Phase 1a data for KRAS G12C NSCLC, with no Grade 2+ adverse events. All three BBOT pipeline candidates are expected to report Phase 1 data in 2026, positioning the company for key clinical catalysts.
BridgeBio Oncology Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DK David Kim Paradigm Biocapital Advisors LP | 868,213 | $10.43M | $6.74M | -$3.69M | -35.38% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 4 | $36 | $31.04 | -$4.96 | -13.78% |
BridgeBio Oncology Therapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JN John Newman Canaccord Genuity | 104 | $820.59 | $807.07 | -$13.52 | -1.65% |
BridgeBio Oncology Therapeutics, Inc. (BBOT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BridgeBio Oncology Therapeutics, Inc. ever had a stock split?
BridgeBio Oncology Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Eli Wallace CEO | NASDAQ (NMS) Exchange | 107924102 CUSIP |
| US Country | 62 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing next-generation small molecule therapeutics that specifically target RAS and PI3Kα malignancies. These oncogenes are commonly found in human tumors, leading to a significant prevalence of associated cancers. Initially established as a subsidiary of BridgeBio Pharma, the company is committed to precision oncology, focusing on a robust pipeline aimed at addressing critical unmet medical needs within the oncology space. Recent milestones include going public through a strategic business combination with Helix Acquisition Corp. II, a move that successfully raised approximately $450 million to bolster clinical development efforts. The organization is spearheaded by CEO Dr. Eli Wallace and Chief Scientific Officer Dr. Pedro Beltran, both of whom bring extensive experience in biopharmaceutical development.
Products and Services
- BBO-8520
BBO-8520 is an innovative therapeutic candidate targeting the KRAS pathway. Designed to inhibit the malignant effects of mutated KRAS genes, this drug aims to provide a targeted treatment option for patients suffering from KRAS-driven tumors, which are particularly challenging to treat due to their aggressive nature.
- BBO-10203
This product focuses on the PI3Kα pathway, aiming to impede the signaling mechanisms that contribute to tumor growth and survival. BBO-10203 represents a promising approach in precision medicine, specifically for patients whose cancers exhibit mutations in the PI3K pathway.
- BBO-11818
BBO-11818 is another critical program under development that addresses both RAS and PI3K-related oncogenic pathways. This compound seeks to offer a dual-targeted treatment approach, potentially enhancing therapeutic efficacy while minimizing off-target effects commonly associated with traditional therapies.
